BSAC is delighted to announce the award of eleven grants from the first COVID-19 funding call.  The call was aimed at supporting how to better understand and address the COVID-19 pandemic outbreak.  The Society will announce and open a 2nd call for grant applications on Monday 15th June.  

The following grants have been awarded:

• Targeting intracellular vesicular trafficking using a novel V-ATPase inhibitor to ameliorate pathogenicity of SARS-CoV-2 and related viral pathogens, King’s College London
• “Control of COVID-19 outbreaks in long term care (CONTROL-COVID)”, University of Toronto
• Characterising the effects of immune-modulating drugs on the T cell immune response to COVID 19, King’s College London
• Utilising novel antimicrobial agents to restore dysregulated immunity to SARS-CoV-2 in high risk patients, Imperial College London
• A scalable workflow for rapid population-wide diagnostics of COVID-19, King’s College London
• Accelerated introduction of a novel class of resistance-proof antiviral drugs: Strathclyde Minor Groove Binders University of Strathclyde, Glasgow
• Harnessing High Performance Computing Tools in a COVID-19 Drug Repurposing Pipeline, University of Bristol, Bristol
• The anti-viral and anti-cytokine effects of baricitinib: stitching together a dual mechanism, Imperial College/ Imperial Healthcare NHS Trust, London
• Intramolecular trans-sialidase as alternative therapeutics against COVID-19, Quadram Institute Bioscience, Norwich Research Park, Norwich
• Development of a novel small non-antibody protein scaffold as a therapy to reduce the SARS-Cov2 viral load Poseidon LLC, Pasadena, California
• A humanized mouse model of COVID-19 harnessing the clinical potential of patient-derived antibodies, Yale University and Howard Hughes Medical Institute, New Haven, Connecticut

HISTORY OF GRANTS AWARDED: Grants Awarded 2005-2020